Smith T W
J Pharmacol. 1984;15 Suppl 1:35-51.
A broad survey of the experimental literature suggests that the only unifying concept of digitalis action is that these drugs, at pharmacologically relevant doses, bind with high affinity and specificity to sites on the NaK-ATPase complex that face the outer surface of nearly all eukaryotic cells. Alternative receptors, if they exist, have not been defined. As might be expected, a broad range of biologic effects results from this basic interaction. The clinical therapeutic effects of digitalis include enhancement of myocardial contractility and changes in the properties of the cardiac conduction system; the latter, in turn, result from both direct and autonomically mediated effects [44]. Autonomic effects involve alterations in both parasympathetic and sympathetic activity, and these are attributable to both central and peripheral neural mechanisms [44]. As we have reviewed, there is compelling evidence that one mechanism leading to sustained positive inotropic effects of digitalis glycosides in heart muscle is partial inhibition of sodium transport. Earlier evidence [16, 17] is now supported by electrophysiologic studies [29, 30, 45, 46], intracellular ion-sensitive microelectrode methods [47, 48], and ion flux measurements using radioisotope tracers [14, 15, 49]. Inhibition of myocardial monovalent cation transport has been documented in intact glycoside-sensitive animal models at doses and plasma and myocardial levels causing a positive inotropic effect without overt toxicity [12]. However, these findings do not preclude other mechanisms that may be operative in addition to, or in some circumstances instead of, myocardial Na-K pump inhibition. In the context of much seemingly conflicting evidence [35, 36, 37, 50, 51], the hypothesis advanced by Akera and Brody is of interest [17]. These authors suggest that interaction of subtoxic digitalis concentrations with myocardial NaK-ATPase reduces maximum sodium transport capacity, resulting in an enhanced transient increase in [Na]i during the early phase of the cardiac cycle. Such an increase in subsarcolemmal [Na+] could cause increased Ca++ influx via Na+-Ca++ exchange, with a consequent positive inotropic effect. If the Na+ increase were cyclic and not cumulative, cell Na+ content could return to normal by the end of a cycle due to enhanced turnover of unblocked Na-K pump sites. This hypothesis suggests a mechanism by which Na-K pump inhibition could cause a positive inotropic effect without any measurable increase in steady-state [Na+]i or decrease in [K+]i.(ABSTRACT TRUNCATED AT 400 WORDS)
对实验文献的广泛调查表明,洋地黄作用的唯一统一概念是,这些药物在药理学相关剂量下,以高亲和力和特异性与几乎所有真核细胞外表面的钠钾 - ATP酶复合物位点结合。如果存在其他受体,则尚未明确。正如预期的那样,这种基本相互作用会产生广泛的生物学效应。洋地黄的临床治疗作用包括增强心肌收缩力以及改变心脏传导系统的特性;后者又源于直接和自主介导的效应[44]。自主效应涉及副交感神经和交感神经活动的改变,这归因于中枢和外周神经机制[44]。正如我们所综述的,有令人信服的证据表明,洋地黄苷在心肌中产生持续正性肌力作用的一种机制是部分抑制钠转运。早期证据[16,17]现在得到了电生理研究[29,30,45,46]、细胞内离子敏感微电极方法[47,48]以及使用放射性同位素示踪剂的离子通量测量[14,15,49]的支持。在完整的对糖苷敏感的动物模型中,已记录到在引起正性肌力作用而无明显毒性的剂量、血浆和心肌水平下,心肌单价阳离子转运受到抑制[12]。然而,这些发现并不排除除心肌钠钾泵抑制之外,或在某些情况下替代心肌钠钾泵抑制的其他可能起作用的机制。在许多看似相互矛盾的证据[35,36,37,50,51]的背景下,阿凯拉和布罗迪提出的假说很有意思[17]。这些作者认为,亚中毒剂量的洋地黄与心肌钠钾 - ATP酶的相互作用会降低最大钠转运能力,导致在心动周期早期[Na]i的瞬时增加增强。肌膜下[Na +]的这种增加可通过钠 - 钙交换导致钙内流增加,从而产生正性肌力作用。如果钠的增加是周期性的而非累积性的,由于未被阻断的钠钾泵位点的周转增强,细胞钠含量在一个周期结束时可恢复正常。这个假说提出了一种机制,通过该机制钠钾泵抑制可导致正性肌力作用,而稳态[Na +]i没有任何可测量的增加或[K +]i没有降低。(摘要截取自400字)